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86 Abstract Purpose: Osteoporosis remains a major public health concern, considering its
high prevalence along with its association with osteoporotic fractures. It
imposes a heavy burden on the society worldwide as the population ages. This
paper aims to provide a brief review on Iranian multicenter osteoporosis studies
(IMOS) studies and provide some recommendations for improvement.
Methods: IMOS studies were conducted to investigate the prevalence of
osteoporosis and related risk factors. This paper provides a general view on the
Iranian multicenter osteoporosis studies (IMOS), conducted during last
decades.
Results: The results showed a high prevalence of osteoporosis and vitamin D
deficiency in the Iranian population. Although the study protocols were mainly
similar, some differences were observed in terms of the study population and
design. The protocol of IMOS-3 was modified to overcome the setbacks noted
in the previous studies; however, it was implemented in two cities with
noticeably different socioeconomic and geographical characteristics from five
cities where the first phase was conducted, resulting in different lifestyles and
habits. Although previous IMOS studies have raised major concerns regarding
the high prevalence of osteoporosis and vitamin D deficiency, interpretation
should be made with caution given the differences, especially in the surveyed
cities. Such discrepancies cause problems in trend analysis, and nationally
representative samplings are preferably needed to correctly compare the
prevalence of osteoporosis and related risk factors.
Conclusions: Considering the aging population and the importance of
osteoporosis and its complication, developing a standard surveillance system to
obtain valid and nationally representative estimates is recommended.
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12 Abstract
13 Purpose Osteoporosis remains a major public health concern, considering its high prevalence along with its association with
14 osteoporotic fractures. It imposes a heavy burden on the society worldwide as the population ages. This paper aims to provide a
15 brief review on Iranian multicenter osteoporosis studies (IMOS) studies and provide some recommendations for improvement.
16 Methods IMOS studies were conducted to investigate the prevalence of osteoporosis and related risk factors. This paper provides
17 a general view on the Iranian multicenter osteoporosis studies (IMOS), conducted during last decades.
18 Results The results showed a high prevalence of osteoporosis and vitamin D deficiency in the Iranian population. Although the
19 study protocols were mainly similar, some differences were observed in terms of the study population and design. The protocol of
20 IMOS-3 was modified to overcome the setbacks noted in the previous studies; however, it was implemented in two cities with
21 noticeably different socioeconomic and geographical characteristics from five cities where the first phase was conducted,
22 resulting in different lifestyles and habits. Although previous IMOS studies have raised major concerns regarding the high
23 prevalence of osteoporosis and vitamin D deficiency, interpretation should be madewith caution given the differences, especially
24 in the surveyed cities. Such discrepancies cause problems in trend analysis, and nationally representative samplings are preferably
25 needed to correctly compare the prevalence of osteoporosis and related risk factors.
26 Conclusions Considering the aging population and the importance of osteoporosis and its complication, developing a standard
27 surveillance system to obtain valid and nationally representative estimates is recommended.
28 Keywords Osteoporosis . Iran . Prevalence . VitaminD deficiency
29
30 Introduction
31 OQ1 steoporosis, characterized by fragile bones, develops gradu-
32 ally and is often diagnosed when a minor fall or light trauma
33causes bone fracture. Worldwide, approximately one-tenth of
34women aged 60 and over are affected by osteoporosis [1].
35Osteoporosis imposes a heavy burden on the patient and the
36society. Fractures are the common complications and
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37 annually, account for a global loss of 5.8 million healthy life
38 years due to disability [2].
39 According to a study published in 2005, Iran accounts for
40 12.4% of the total burden of hip fracture in the Middle East.
41 The Disability Adjusted Life Years attributable to hip fracture
42 was estimated at 16,708 years including 8,812 (52.7%) Years of
43 Life Lost and 7,896 (47.3%) Years Lived with Disability [3].
44 Iran has experienced an upward trend in life expectancy
45 during the past two decades resulted in increasing proportion
46 of the population aged ≥ 60 years [4]. As a result, in parallel
47 with the global trends [5], the country is facing a surge in the
48 number of at-risk population for osteoporosis. The prevalence
49 of osteoporosis at either hip or lumbar site among Iranians
50 aged ≥ 50 years was 22.2% in women and 11.0% in men in
51 2010. The corresponding values for osteopenia were 59.9%
52 and 50.1%, respectively [6]. Bone loss was also detected in
53 almost 33.0% of women and 31.6% of men younger than
54 50 years [6, 7]. A recent meta-analysis showed the prevalence
55 of osteoporosis at lumbar spine in Iran to be about 12% in men
56 and 19% in postmenopausal women; however, the values
57 were heterogeneous. For instance, the prevalence in men
58 ranged from 8–22% in 2004 and from 6–31% in 2008 [8].
59 Some studies have also showed the high prevalence of related
60 risk factors such as vitamin D deficiency [9, 10] and physical
61 inactivity [11] in the Iranian population.
62 Regarding the preventable nature of osteoporosis and relat-
63 ed complications, illustrating a comprehensive picture of the
64 related risk factors and their nation-wide distribution can help
65 pave the way to adopt more effective strategies by
66 policymakers. The Iranian Multicenter Osteoporosis Studies
67 (IMOS) are a group of national studies conducted by the
68 Endocrinology and Metabolism Research Institute affiliated
69 with Tehran University of Medical Sciences, and the Iranian
70 Ministry of Health and Medical Education to establish a foun-
71 dation for public health interventions.
72 As we are on the verge of conducting the new round of
73 IMOS, we reviewed the main national surveys on osteoporo-
74 sis, with a special focus on their study design. In this study we
75 have tried to summarize and present the points and lessons
76 learned from these studies that we believe can help improve
77 future studies to be conducted in this regard.
78 Material and methods of different phases
79 of the IMOS Studies
80 The main objectives of the IMOS projects were: (i) to assess
81 the standardized prevalence of osteoporosis and osteopenia,
82 (ii) to determine the age of peak bone mass, and (iii) to deter-
83 mine the prevalence of serum vitamin D deficiency and other
84 osteoporosis risk factors in different urban areas.
85 The first phase, IMOS-1, was conducted in 2001. A ran-
86 dom cluster sampling method was used [2, 12] and a total of
875,339 healthy men and women aged between 20 and 76 years
88were enrolled from urban areas of five main cities (Tehran,
89Mashhad, Shiraz, Tabriz, and Bushehr) [13, 14]. The exclu-
90sion criteria were having a history of rheumatoid arthritis, type
911 diabetes mellitus, thyroid, parathyroid, adrenal, renal or car-
92diac diseases, history of infertility, oligomenorrhea, malignan-
93cy, malabsorption, long-term immobilization, pregnancy,
94breastfeeding, and alcoholism as well as taking medications
95affecting bone metabolism [2, 14].
96The second phase, (IMOS-2), was conducted in 2005 in
97two Iranian cities (Sari and Yazd), using a nearly similar re-
98cruitment process and protocol [13]; almost 1400 men and
99women aged between 20 and 70 years were recruited.
100Besides the exclusion criteria of IMOS-1, individuals with
101history of illicit drug use or supplementation (calcium, at least
102one tablet per day and/or vitamin D, oral consumption during
103past three months or injection during past year), and profes-
104sional athletes as well as those with a vertebral fracture or
105history of any falls leading to fracture and hospitalization in
106two weeks prior to the study were excluded (unpublished
107protocol).
108In the first two phases of IMOS, from each house, only one
109person from a randomly defined age range was invited for the
110study [15]. One fasting blood sample was taken from each
111participant in his/her place of residence, in winter. Samples
112centrifuged and serum extraction was done in that city’s lab.
113Then samples were frozen immediately and were sent to the
114EMRC laboratory for analysis [13].
115The third phase, (IMOS-3), was conducted in Arak and
116Sanandaj in 2011. These two cities were selected because of
117their considerably different socioeconomic and geographical
118characteristics, resulting in different lifestyles and habits.
119Using a one–stage cluster sampling, a total of 2,100 Iranian
120adults, aged ≥ 20 years were enrolled from urban areas of
121these two cities. All the adults who met the inclusion criteria
122in these families and adjacent households, based on the census
123list, were recruited until 15 individuals were included in each
124cluster. The interviewers were asked to visit the households in
125the afternoons, which was a better time for all family mem-
126bers. The individuals, who agreed to sign an informed consent
127form, were asked to fill a questionnaire at the time of the visit
128and then referred for laboratory and bone mineral density test-
129ing upon the arranged time [16].
130The protocol was modified to overcome the setbacks noted
131in the previous phases [16]. Individuals with any mental/
132psychological problems, those unable to cooperate with the
133interviewers, those with a deformity in the spine, hip or lower
134extremities that would affect BMD results, those whoweighed
135more than 120 kg as well as those who were hospitalized for
136more than 2 weeks or immobilized for more than 3 consecu-
137tive months were excluded. Individuals suffering from infer-
138tility, acute/chronic renal failure, advanced liver failure, any
139kind of cancer, chronic diarrhea, mal-absorption and those
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140 taking any type of vitamin D in the past 6 months were also
141 excluded [16].
142 Design characteristics of the three IMOS studies were sum-
143 marized in Table 1.
144
145 Measurements
146 In IMOS-1, the participants completed a questionnaire, main-
147 ly collecting information on their life-style (physical activity,
148 sun exposure, diet) along with past medical and drug history.
149 Along with the information gathered in IMOS 1, an additional
150 questionnaire was designed for the female head of household
151 or the oldest woman living in the house in IMOS-3 to assess
152 their knowledge of osteoporosis [16].
153 Using Dual-energy X-ray Absorptiometry technique, the
154 BMD was measured in IMOS studies [13, 16]. Since the de-
155 vices were not exactly the same in study centers, sBMD was
156 used to facilitate the conversion and comparability of results
157 between the cities.
158Related biochemical parameters were tested in all phases;
159moreover, in phase 3 whole blood samples were collected for
160genetic studies and DNA was extracted. Neither the measure-
161ment of knowledge on osteoporosis nor the genomic studies
162were performed in the first two phases of IMOS studies.
163Results
164The results of IMOS-1 showed that 78.2% of postmenopausal
165women and 77.3% of men aged 50 years and older had
166osteopenia or osteoporosis [12]. Comparing the prevalence
167of osteoporosis in the over 50-year-old population showed a
168higher prevalence among females (28% in men and 35.2% in
169women) [12]. As for individuals aged less than 50 years, men
170showed higher prevalence of bone loss at femoral neck and
171total hip [17]. In IMOS- III prevalence of osteoporosis in men
172aged ≥ 50 years and in postmenopausal women were 44% and
17337%, respectively [18].
174The prevalence of moderate to severe vitamin D deficiency
175in IMOS-1 was 47.2%, 45.7% and 44.2% in men aged < 50,
t1:1 Table 1 Design characteristics of the three IMOS studies
t1:2 IMOS-I IMOS-II IMOS-III
t1:3 Year 2001 2005 2011
t1:4 Location Tehran, Mashhad, Shiraz, Tabriz, and
Bushehr
Sari and Yazd Arak and Sanandaj
t1:5 Age/Gender men and women aged between 20 and
76 years
men and women aged between
20 and 70 years
Adults aged ≥ 20 years
t1:6 Sample size 5339 1400 2100
t1:7 Measurements 1. Lab data
2. Life-style (physical activity, sun
exposure, diet) along with
past medical and drug history
3. BMD
1. Lab data
2. life-style (physical activity, sun




2. Life-style (physical activity, sun exposure,
diet) along with past medical and drug
history.
3. knowledge of osteoporosis of the female
head of household or the oldest woman




Healthy men and women aged
between 20 and 76 years from urban
area
men and women aged between 20 and
70 years from urban area
aged ≥ 20 years from urban areas
t1:9 Exclusion
Criteria
having a history of rheumatoid arthritis,
type 1 diabetes mellitus, thyroid,
parathyroid, adrenal, renal or cardiac




alcoholism as well as taking medications
affecting bone metabolism
history of illicit drug use or
supplementation (calcium, at least one
tablet per day and/or vitamin D, oral
consumption during past threemonths or
injection during past year), and
professional athletes as well as those
with a vertebral fracture or history of any
falls leading to fracture and
hospitalization in two weeks prior to
the study.
Individuals with any mental/psychological
problems, those unable to cooperate with
the interviewers, those with a deformity in
the spine, hip or lower extremities that
would affect BMD results, those who
weighed more than 120 kg as well as
those who were hospitalized for more
than 2 weeks or immobilized for more
than 3 consecutivemonths were excluded.
Individuals suffering from infertility,
acute/chronic renal failure, advanced liver
failure, any kind of cancer, chronic
diarrhea, mal-absorption and those taking
any type of vitamin D in the past 6 months
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176 50–60 and ≥ 60 years, respectively. The data from Bushehr
177 were not included due to the heterogeneity of the data. In
178 women of the same age, these values were 54.2%, 41.2%
179 and 37.5%, correspondingly [9]. The highest rate of moderate
180 to severe vitamin D deficiency was noted in Tehran [9, 19]. In
181 IMOS-3, 66.4% of the studied population suffered from vita-
182 min D deficiency. The rate was significantly higher in women
183 (68% vs. 63%, p = 0.02). Deficiency was more prevalent in
184 participants aged less than 50 (68% vs. 61%, p < 0.01).
185 Prevalence of vitamin D deficiency was higher in women
186 aged less than 50 while in men, the higher prevalence was
187 detected in population aged > 50 years. The difference be-
188 tween prevalence of vitamin D deficiency in men and women
189 was statistically significant (57% vs. 68%, p < 0.01).
190 Osteoporosis in either site was detected in 35% of men and
191 36% of women aged over 50 years (Unpublished data).
192 The results of logistic regression analysis in IMOS-1
193 marked age, female sex and menopause as the main risk fac-
194 tors for osteoporosis [2]. As expected, BMD was shown to be
195 significantly positively correlated with weight, height, body
196 mass index (BMI) and waist-to-hip ratio in both genders( all
197 correlations were positive with p-value < 0.05) [20].
198 The results showed that 81.3% of the female head of house-
199 hold in IMOS-3 had a poor knowledge of different aspects of
200 osteoporosis and its complications. It was also shown that
201 higher level of osteoporosis-related knowledge was associated
202 with an increase in vitamin D intake [21].
203 Discussion
204 IMOS studies showed that roughly one-third and half of the
205 Iranian population aged > 50 years suffered from osteoporosis
206 and osteopenia, respectively. The results also showed high
207 prevalence of vitamin D deficiency among Iranians. On the
208 other hand, poor knowledge of the disease was reported
209 among women head of households, who play an important
210 role in the life style of the family including the eating and
211 physical activity habits.
212 Consistent with IMOS studies, a meta-analysis of the pub-
213 lished studies in the Eastern Mediterranean Region showed
214 the prevalence of osteoporosis to be as high as 24.4% (95%
215 CI, 20.4–28.2) in postmenopausal women and men aged ≥
216 50 years. The prevalence was significantly higher in 2007–
217 2015 compared with that of 2000–2006 [22]. These figures
218 indicate an urgent need for special attention by health service
219 authorities.
220 Apart from osteoporosis, IMOS studies were tailored to
221 assess the incidence of osteoporosis-associated risk factors,
222 and their changes over time. In general, to assess the severity
223 of health issues and the effect of intervention, repeated cross-
224 sectional surveys are recommended. Independent samples col-
225 lected at each round of survey studies are generally perceived
226as desirable data that can provide harmonized information on
227the outcome. To maximize comparability, a similar sampling
228design with standard protocols and questionnaires, consistent
229definition of the study population, variables and indicators as
230well as equivalent measurement techniques are highly recom-
231mended. These studies are more cost-effective and desirable
232when marginal probabilities are of interest [23].
233Limitations
234Although IMOS studies have highlighted the importance of
235osteoporosis and Vitamin-D deficiency in Iran, and in each
236phase have tried to address some of the shortcomings of the
237previous stages, all IMOS studies were conducted in capital
238cities due to logistic constraints, and thus may not be repre-
239sentative of the urban population of smaller cities or rural
240areas. This is while 26% of the Iranian population live in rural
241areas, and so there is scarce information on bone health of
242rural population (https://www.amar.org.ir/#5538643).
243Recommendations and the way forward for the
244scientific community
245& Regarding the high burden of osteoporosis and osteopo-
246rotic fractures and the importance of evidence-based pol-
247icy, the results need to be updated since the last IMOS
248study was conducted in 2011. The results of prevalence
249studies are dependent on the study site. For example, ac-
250cording to the STEPS Survey in 2016 [24], the prevalence
251of smoking in men varied from 20% in South Khorasan to
252nearly 55% in Qazvin. The prevalence of vitamin D defi-
253ciency also varies in different regions of Iran from 33.5%
254(95%CI: 28.8–38.3) to 80.3 (95%CI: 76.6–84.1) among
255men and from 31.0 (95%CI: 21.9–40.1) to 91.0 (95% CI:
25688.9–93.2) among women [10].
257& To overcome the challenge of such heterogeneity, cluster-
258ing approach is recommended. to have a nationally repre-
259sentative sample, clustering by the potential effective
260osteoporosis-related factors, such as nutrition, urbaniza-
261tion index, wealth index, physical activity, dairy consump-
262tion, etc. should be used. The proposedmethod guarantees
263that the sample is well spread in different parts of the
264country.
265& The peak bone age was determined in previous phases of
266IMOS studies. Considering the main goals of IMOS study
267in the next phase, which is determining the prevalence and
268related risk factors in the at-risk population, limiting the
269survey on the elderly population would be recommended
270to reduce the sample size and logistic constraints.
271& Sarcopenia, defined as reduced muscle mass with limited
272mobility, is currently considered as an important health
273issue and suspected older individuals should be screened
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274 for this problem [25]. The muscles and the skeletal sys-
275 tems are closely interconnected as a “hazardous duet,”
276 [26] and the combination of osteoporosis and sarcopenia,
277 may increase the probability of falls, leading to fragility
278 fractures [27, 28]. There is no nationally representative
279 information about the prevalence of sarcopenia; however,
280 the prevalence of sarcopenia in 2011 in Tehran was re-
281 ported to be as high as 20.7% inmen and 15.3% in women
282 [29]. Taking into account the common risk factors and
283 complications of osteoporosis and sarcopenia, identifying
284 the prevalence and related risk factors of sarcopenia in the
285 next round of IMOS is recommended.
286 Point to be considered in designing the national
287 repeated surveys
288 & Repeated surveys make the opportunity for the trend anal-
289 ysis that summarizes the patterns across time and helps to
290 estimate the current and previous interested variables and
291 their changeability and uncertainties during different peri-
292 od of time. considering the significance of time and asso-
293 ciations with other prognostic factors, these studies pro-
294 vide a basis for further study in prediction and projection
295 and also could provide essential recommendations for the
296 policymakers to prioritize the problems for better resource
297 allocations.
298 & To achieve the stated goals, some critical points should be
299 considered, e.g. survey design adjustment, specify survey
300 sampling units, strata and applying appropriate weights.
301 There is also a need for the identification of necessary
302 variables that requires expert knowledge and a deep liter-
303 ature review. Variable measurements should also be har-
304 monized to better comparison between studies.
305 & National surveys may impose huge cost to the health sys-
306 tem, so using approaches to reduce the study cost is pref-
307 erable. One of the most recommended design is cluster
308 sampling that reduce the costs, given the predefined accu-
309 racy and having the nationally representative data.
310 Clustering could be applied in different ways such as
311 model-based clustering. In this method, using a statistical
312 modeling, a country is divided into different geographical
313 zones; each zone consists of provinces that are similar in
314 terms of the variables related to the interested outcome.
315 Conclusions
316 Osteoporosis and osteoporotic fractures impose a heavy bur-
317 den on health systems worldwide. Understanding the epide-
318 miology of osteoporosis is necessary to develop strategies to
319 reduce its burden. National systematic studies to identify the
320changes over time are lacking; strengthening osteoporosis sur-
321veillance through developing repeated nation-wide surveys
322are recommended.
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